MDMaren Darsow

Maren Darsow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maren Darsow has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials

    by Brooke M. Felsheim, Jens Huober, Lisa A. Carey, Valentina Nekljudova, Thomas Karn, Sara M. Tolaney, Andreas Schneeweiss, Michael Untch, Christoph Salat, Charles S. Kuzma, et al.

    Purpose: To better characterize the therapeutic benefits of the addition of carboplatin to anthracycline- and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC), we performed a pooled analysis of three randomized clinical trials: BrighTNess (ClinicalTrials.gov identifier: NCT02032277 ), Cancer and Leukemia Group B 40603 (ClinicalTrials.gov identifier: NCT00861705 ), and GeparSixto (ClinicalTrials.gov identifier: NCT01426880 ). Methods: We evaluated the impact of the addition of carboplatin to NACT on pathologic complete response (pCR) rates, event-free survival (EFS), and overall survival (OS) across a combined total of 1,084 patients. We additionally looked for associations of outcome by germline BRCA1 and BRCA2 (g BRCA ) mutation status, eight gene expression signatures, and molecular subtypes (PAM50, MD Anderson Cancer Center/Baylor College of Medicine [MDACC/BCM]). Results: In the pooled data set, the addition of carboplatin to NACT was associated with a higher pCR rate (odds ratio, 1.89 [95% CI, 1.41 to 2.55]; P < .001) and improved EFS (hazard ratio, 0.71 [95% CI, 0.54 to 0.93]; P = .01), but not OS. In patients with g BRCA mutations (n = 137), we found that the addition of carboplatin conveys a significant EFS benefit but had no significant association with pCR rate or OS. We found six immune gene expression signatures that were significantly associated with a higher pCR rate and four that were significantly associated with improved EFS and OS. In addition, we found that the PAM50 luminal and MDACC/BCM luminal androgen receptor molecular subtypes were significantly associated with lower pCR rates in the combined data set. Conclusion: Our findings support the recent addition of carboplatin to NACT within the standard-of-care treatment of stage II to III TNBC and emphasize the importance of the TNBC immune microenvironment to patient outcomes.

  • Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

    by Ulrike A Nitz, Oleg Gluz, Sherko Kümmel, Matthias Christgen, Michael Braun, Bahriye Aktas, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, et al.

    PURPOSE: To our knowledge, WSG-ADAPT-HR+/HER2– (ClinicalTrials.gov identifier: NCT01779206 ; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) to guide systemic therapy in early breast cancer. MATERIALS AND METHODS: Baseline and postendocrine Ki67 (Ki67post) were evaluated centrally. In the endocrine trial, all patients received exclusively ET: patients with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved lymph nodes) entered control arm if RS ≤ 11 and experimental arm if RS12-25 with ET response (Ki67post ≤ 10%). All other patients (including N0-1 RS12-25 without ET response) received dose-dense chemotherapy (CT) followed by ET in the CT trial. Primary end point of the endocrine trial was noninferiority of 5-year invasive disease-free survival (5y-iDFS) in experimental ( v control) arm; secondary end points included distant DFS, overall survival, and translational research. RESULTS: Intention-to-treat population comprised 2,290 patients (n = 1,422 experimental v n = 868 control): 26.3% versus 34.6% premenopausal and 27.4% versus 24.0% pN1. One-sided 95% lower confidence limit of the 5y-iDFS difference was –3.3%, establishing prespecified noninferiority ( P = .05). 5y-iDFS was 92.6% (95% CI, 90.8 to 94.0) in experimental versus 93.9% (95% CI, 91.8 to 95.4) in control arm; 5-year distant DFS was 95.6% versus 96.3%, and 5-year overall survival 97.3% versus 98.0%, respectively. Differences were similar in age and nodal subgroups. In N0-1 RS12-25, outcome of ET responders (ET alone) was comparable with that of ET nonresponders (CT) for age > 50 years and superior for age ≤ 50 years. ET response was more likely with aromatase inhibitors (mostly postmenopausal) than with tamoxifen (mostly premenopausal): 78.1% versus 41.1% ( P < .001). ET response was 78.8% in RS0-11, 62.2% in RS12-25, and 32.7% in RS > 25 (n = 4,203, P < .001). CONCLUSION: WSG-ADAPT-HR+/HER2– demonstrates that guiding systemic treatment by both RS and ET response is feasible in clinical routine and spares CT in pre- and postmenopausal patients with ≤ 3 involved lymph nodes.


  • Open Access

    Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)

    by T. Schaper, M. Rezai, G. Petruschke, B. Gross, L. Franzmann, M. Darsow

    Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of many commonly used chemotherapeutic agents, especially taxane-based regimen (Paclitaxel, nab-Paclitaxel, Docetaxel). The CIPN reduces patients health-related quality of life for years and often results in dose delay, dose reduction or treatment discontinuation. The prophylactic use of controlled cryotherapy (Hilotherapy®) prevents chemotherapy-induced-peripheral neuropathy (CIPN). 162 breast cancer patients treated with taxane based therapeutic regimen used prophylactic Hilotherapy® to cool hands and feet during chemotherapy infusion between 10/2016 – 02/2019. Hilotherapy® is a new physical thermotherapy device, equiped with hand and foot cuffs to allow a constant cooling in a localized and targeted manner. Continous cooling of hands and feet was performed 30 minutes before to 60 minutes after completing drug infusion with a temperature of 10-12 °C. CIPN symptoms were evaluated after each treatment cycle using common terminology criteria for adverse events (CTCAE). The sustainability of the impact was assessed by long-term datas (Follow Up patient contact every 3 months). 122 patients have finished their chemotherapy treatments with prophylactic hand-feet cooling using Hilotherapy®, 39 patients are still under therapy. 113 patients (92.6%) developed none or mild symptoms of CIPN (grade 0-1). 8 patients (6,6%) reported grade 2 toxicity, 1 patient grade 3 (0,8%). The symptoms of CIPN were reversible. Four weeks after the last chemotherapy treatment, 5 patients (4,5%) still reported grade 2 toxicity, none of them suffered from grade 3. Another 3 months later, 2 patients (2,2%) reported an intermittent toxicity of grade 2. Long-term Follow Up datas confirm the lasting results. Prophylactic Hilotherapy® prevented limiting CIPN Symptoms (> grade 1) in 93% of patients. 7% of the patients developed reversible toxicities grade 2/3. 4 months after chemotherapy treatment, all patients were without any limiting symptoms (grade ≤ 1), except two patients (grade 2). No dose modifications or treatment interruptions had been necessary. The authors. Hilotherm GmbH. T. Schaper: Honoraria (self), Advisory / Consultancy: Paxman; Honoraria (self), Travel / Accommodation / Expenses: Hilotherm; Honoraria (self), Advisory / Consultancy: EAoS; Honoraria (self): Roche. M. Darsow: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Amgen. All other authors have declared no conflicts of interest.


  • Breast-Conserving Treatment of Breast Cancer – Oncological and Reconstructive Aspects

    by Stefan Krämer, Maren Darsow, Sherko Kümmel, Rainer Kimmig, Mahdi Rezai

    Breast-conserving surgery combined with radiotherapy has become the treatment of choice for the majority of women presenting with primary breast cancer over the last 20 years. The extent of local excision remains a controversial issue in breast-conserving surgery. The wider the margins of clearance, the lower the risk of incomplete excision and thus of local recurrences, but the greater the amount of tissue removed, the higher the risk of visible deformity leading to an unacceptable cosmetic result. This clash of interests is most evident when attempting breast-conserving surgery in patients with smaller breast-tumor ratios. The widespread popularity of breast-conserving surgery has focused attention on new oncoplastic techniques that can avoid unacceptable cosmetic results. Partial mastectomy defects can be reconstructed by volume displacement, recruiting and transposing local glandular or dermoglandular flaps into the resection site, or by volume replacement, importing volume from elsewhere to replace the amount of tissue resected.